On the World Parkinson’s Day, Zambon announces Synapses study’s results on Parkinson’s patients in real special settings

The real-world Synapses study confirms the safety and tolerability of safinamide used as an adjunct therapy in patients with fluctuations mainly older, with comorbidities or psychiatric conditions.

On the occasion of the World Parkinson's Day occurred yesterday, Zambon officially presents results from its SYNAPSES study aimed at investigating the real-world use of safinamide in six European countries.

Safinamide is a multimodal drug with a dual mechanism of action, dopaminergic (reversible mono-amine oxidase-B inhibition) and non-dopaminergic (modulation of the abnormal glutamate release), that offers an innovative approach to the management of motor and non-motor symptoms and motor complications.